Drug Profile
Anti-CD3 anti-HER2 bi-specific antibody - Genentech
Alternative Names: Anti-HER2-anti-CD3 activated T cells; HER2-TDB; HER2/CD3; Trastuzumab-based HER2 T cell dependent bispecific antibodyLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen stimulants; ERBB 2 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Breast cancer in USA (Parenteral) (Genentech pipeline, September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 09 Apr 2016 Preclinical trials in Breast cancer in USA (Parenteral)